



an Open Access Journal by MDPI

Allogeneic Cell Cancer Immunotherapies

Guest Editor:

Prof. Alan Trounson

Hudson Institute of Medical Research, Monash University and Cartherics Pty. Ltd., Clayton, Australia

Deadline for manuscript submissions: closed (20 October 2021)

Message from the Guest Editor

Dear Colleagues,

Allogeneic immuno-cell therapies are beginning to replace autologous chimeric antigen receptor technologies (CAR-T). The major problem is the recognition of allogeneic cells by the recipient immune system that risks donor cell rejection and graft versus host disease. Given the success of CAR-T for B cell blood cancers, considerable effort is underway to enable single CAR-T products to treat large numbers of patients in a cost-effective way. The ability of gene stem cells to insert CARs into safe harbor sites in the genome and to knock out checkpoint inhibitor genes that prevent tumor destruction is being trialed in animal models and in early-stage clinical trials. These studies are targeted at multiple blood and solid cancers, and also at cells infected with pathological viruses such as HIV and COVID-19. Early progress is encouraging, but the outcome of human clinical trials remains essential to evaluate the safety and efficacy of these new allogeneic cell therapy approaches.

Prof. Alan Trounson









an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Contact Us

Cells Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/cells cells@mdpi.com X@Cells_MDPI